Next Investors logo grey

Lifespot teams up with market leading IONIC

Published 02-JUL-2019 10:31 A.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Lifespot Health Ltd (ASX:LSH) has signed an exclusive Heads of Agreement with IONIC Brands Corp. (CSE:IONC) (OTC:IONKF) (FRA:IB3) to develop and distribute Lifespot’s software and vaporiser technologies.

IONIC is focused on building a multi-state, consumer-focused cannabis concentrate brand portfolio focusing on the premium and luxury segments.

The cornerstone brand of the portfolio, IONIC, is the leading vaporiser brand in Washington State and it has aggressively expanded throughout the west coast of the US.

The brand is currently operating in Washington, Nevada, Oregon and California.

Next Investors Image

IONIC’s strategy is to be the leader of the highest-value segments of the cannabis market while expanding nationally.

Lifespot Health via its subsidiaries, Seng Vital and Bodytel GmbH, will provide its Bluetooth enabled vaporisers that can be used for recreational cannabis and the Bluetooth BodytelTM platform that collects and manages consumer data in a compliant record keeping system that is beneficial to consumers and meets privacy regulations.

Lifespot’s Bodytel has proven track record

This is one of Lifespot’s proven areas of expertise as it is involved in connecting medical diagnostic devices and digital medicine delivery systems via Bluetooth and Smart device APPs to cloud based ISO13485 accredited Bodytel patient management system.

The company’s systems and applications are user-friendly cloud and smartphone-based.

The group’s German based BodyTel system is based on modern and future-proof internet technology utilizing advanced technologies such as document-based databases and biological neural networks.

Next Investors Image

Lifespot and IONIC anticipate that a binding Joint Venture Agreement and Distribution Agreement will be completed within 60 days to formally implement the Joint Venture.

The JV provides 12 months exclusive distribution to IONIC in the United States and Canada and IONIC-owned Astleys of London in the UK.

Additional territories maybe added over time as needed to meet market demand.

Under the Heads of Agreement, the parties intend to collaborate in the development, production and distribution of integrated smart vaporiser products and systems for the recreational cannabis market.

Shipping to commence in September quarter

A purchase order for an initial series of vaporiser and software technologies has been received and will be manufactured exclusively for IONIC.

The company is expected to commence shipping in September quarter of 2019.

Independent of the JV, Lifespot will continue to focus on its product innovation and business development activities with respect to its medical use vaporizer products and systems.

Highlighting the significance of this development, Lifespot executive chairman Rodney Hannington, said, “We are delighted to announce this Heads of Agreement with IONIC, a leading manufacturer and distributor of cannabis concentrate products in the US.

“The company brings hardware and software solutions to IONIC’s great brands and strong and rapidly expanding distribution network.

Next Investors Image

IONIC chairman and chief executive John Gorst underlined the importance of best of breed delivery and dosing technology in saying, “Smartphone Bluetooth technology is the future of cannabis delivery and dosing.

“The company is ecstatic to offer consumers advanced delivery technology that, before this agreement, was only available to medical patients.

“IONIC’s launch and distribution of the Slim-line Vape is expected to start in September quarter of 2019 in Washington, Oregon, Nevada and California.

“The Slim-line Vape is the first Bluetooth enabled vaporiser and platform designed specifically for the use of cannabis.

“Our devices will allow for individual controlled dosing, with maximum safety, and the ability to track and measure progress, including through the use of an innovative fingerprint system.”

Importantly, the implementation of the JV includes the development of integrated quality management systems to ensure strategic and expeditious market entry of new products, and establishment of a highly scalable manufacturing footprint that ensures high volume demand can be met with high quality manufacturing standards.

Next Investors Image

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.